Annual Report 2022

MANAGEMENT DISCUSSION AND ANALYSIS 10 The United Laboratories International Holdings Limited Annual Report 2022 Mr. Leung Wing Hon Vice-Chairman BUSINESS REVIEW AND FINANCIAL RESULTS For the year ended 31 December 2022, the Group recorded revenue of approximately RMB11,334.3 million, an increase of approximately 16.8% as compared with last year. EBITDA was approximately RMB2,640.8 million, representing a year-on-year increase of 40.2%. Profit attributable to owners of the Company was RMB1,581.1 million, representing a year-on-year increase of 60.0%. Earnings per share were RMB86.89 cents. The Board recommended the payment of a final dividend of RMB14 cents per share and a special dividend of RMB6 cents per share for the year ended 31 December 2022. Together with the interim dividend of RMB5 cents per share already paid, the total dividend for the year was RMB25 cents per share. During the year, segmental revenue (including inter-segment sales) of intermediate products, bulk medicine and finished products increased by 27.5%, 32.7% and 13.0% respectively as compared with last year. Segmental result of intermediate products and bulk medicine increased by 131.9% and 90.7% respectively as compared with last year. Segmental result of and finished products decreased by 9.1% as compared with last year.